Enlivex Therapeutics Ltd. Long-Term Debt 2011-2026 | ENLV

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Quarterly Long-Term Debt Enlivex Therapeutics Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	405 K	-	499 K	-	236 K	-	298 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
499 K	236 K	360 K

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Alterity Therapeutics Limited ATHE	59.9 K	$ 3.6	1.34 %	$ 8.66 B	Australia
Aytu BioScience AYTU	10.9 M	$ 2.66	-	$ 16.7 M	USA
BioNTech SE BNTX	231 M	$ 91.28	-	$ 27.2 B	Germany
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	173 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Cerus Corporation CERS	10.2 M	$ 1.85	-	$ 353 M	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	167 M	-	-24.86 %	$ 820 K	USA
Coherus BioSciences CHRS	1.46 M	$ 1.67	-	$ 196 M	USA
Celldex Therapeutics CLDX	784 K	$ 31.37	-	$ 2.08 B	USA
CollPlant Biotechnologies Ltd. CLGN	22.3 K	$ 0.44	-	$ 5.04 M	Israel
Advaxis ADXS	8.14 M	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	86 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
Catalyst Pharmaceuticals CPRX	2.35 M	$ 24.98	-	$ 3.05 B	USA
Corbus Pharmaceuticals Holdings CRBP	1.63 M	$ 10.14	-	$ 135 M	USA
Cardiff Oncology CRDF	102 K	$ 1.58	-	$ 106 M	USA
Curis CRIS	428 K	$ 0.53	-	$ 6.98 M	USA
Crinetics Pharmaceuticals CRNX	42.1 M	$ 37.7	-	$ 3.55 B	USA
CRISPR Therapeutics AG CRSP	188 M	$ 49.15	-	$ 4.42 B	Schweiz
Aeterna Zentaris AEZS	31 K	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	2.95 M	-	-10.17 %	$ 12.2 K	USA
CytomX Therapeutics CTMX	4.24 M	$ 4.4	-	$ 607 M	USA
Citius Pharmaceuticals CTXR	21.3 K	$ 0.86	-	$ 5.79 M	USA
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Cue Biopharma CUE	2.29 M	$ 0.18	-	$ 17.1 M	USA
Applied Genetic Technologies Corporation AGTC	9.12 M	-	-	$ 26.5 M	USA
DBV Technologies S.A. DBVT	5.41 M	$ 20.36	-	$ 2.84 B	France
AIkido Pharma AIKI	2.29 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	193 K	-	-45.71 %	$ 1.2 M	Canada
Denali Therapeutics DNLI	5.62 M	$ 19.38	-	$ 3.19 B	USA
Dyadic International DYAI	34.6 K	$ 0.87	-2.8 %	$ 31.5 M	USA
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	25.4 M	-	-	$ 867 M	Germany
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
Entera Bio Ltd. ENTX	3.89 M	$ 1.19	-	$ 55.5 M	Israel
Equillium EQ	356 K	$ 2.01	-	$ 115 M	USA
Allakos ALLK	38.2 M	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	210 K	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	1.01 B	$ 330.34	-	$ 43.3 B	USA
Alpine Immune Sciences ALPN	3.38 M	-	-	$ 2.17 B	USA
Fate Therapeutics FATE	73.3 M	$ 1.19	-	$ 141 M	USA
Aileron Therapeutics ALRN	69 K	-	10.36 %	$ 9.8 M	USA